Short answer
Nuvalent, Inc. (NUVL) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$109M
- −29.2% YoY
- EPS (diluted)
- −$1.39
- −17.8% YoY
Source: XBRL data from the Nuvalent, Inc. (NUVL) Q1 2026 10-Q on SEC EDGAR. USD.
Nuvalent, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no products approved or commercialized
- Net loss $109.3M vs $84.6M YoY; operating margin not applicable
- Best program NVL-330 R&D $6.8M, up from $4.0M; worst zidesamtinib $12.3M, down from $15.6M
- Cash, equivalents and marketable securities $1.3B; operating cash use $92.4M vs $54.8M
- Funding runway into 2029; headwinds include financing access, inflation and interest-rate volatility
Risk Factors
- Newly triggered regulatory risk: neladalkib NDA submitted to FDA in April 2026, with acceptance and approval uncertain
- Commercialization risk: transition toward commercial operations before zidesamtinib’s September 18, 2026 PDUFA target date
- Clinical-development risk: FDA feedback may require additional pivotal data beyond currently planned trials
- Financial risk: $1.1 billion accumulated deficit and projected operating-cost funding only into 2029
- Market risk: targeted genomic-alteration populations may be too small to support profitable commercialization
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Nuvalent, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.